Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix versus Prevenar 13 primary infant vaccination with Synflorix booster
2013-003479-36Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of 10-valent pneumococcal conjugate vaccine and pneumococcal 13-valent conjugate vaccine in pneumococcal disease and Haemophilus influenzae disease (3 arms), sponsored by GSK. Primary endpoint: Occurrence of grade 3 solicited adverse events.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal diseaseHaemophilus influenzae disease
Beyond the preview
Go deeper on 2013-003479-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003479-36.